**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 72-year-old woman developed hypocalcaemia during treatment with hydrochlorothiazide for arterial hypertension \[*duration of treatment to reaction onset not stated*\].

The woman was hospitalised due to dysarthria and acute perioral paraesthesia. She had a 3-day history of headache and mild fever. Laboratory tests revealed hyperphosphataemia, respiratory alkalosis, slightly increased serum creatinine, and low serum total and ionised calcium level (hypocalcaemia). She also had elevated levels of LDH and CRP along with lymphocytopenia. Anamnesis revealed that she had undergone a total thyroidectomy 19 years previously, and was on levothyroxine sodium treatment. She also had mild renal insufficiency from several years, and arterial hypertension treated with long-term hydrochlorothiazide \[*dosage and route not stated*\] and unspecified ACE inhibitors. She underwent nasopharyngeal swab test for COVID-19 because of contact with a suspect infected subject.

The woman was treated with calcium gluconate for severe hypocalcaemia. She was found to be positive for COVID-19. She also had vitamin-D deficiency with low parathyroid hormone level. The severe hypocalcaemia was considered to be developed secondary to the long-term hydrochlorothiazide therapy. Subsequently, her headache and fever resolved, and the calcium levels normalised. She was discharged 9 days later on calcium carbonate and calcitriol treatment.
